We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Novel Digital Morphology Analyzer Performance Evaluated

By LabMedica International staff writers
Posted on 01 Dec 2022
Print article
Image: The CellaVision DC-1 is a stand-alone hematology analyzer that performs blood cell differentials. It offers a suitable solution for laboratories with small workloads (Photo courtesy of Sysmex)
Image: The CellaVision DC-1 is a stand-alone hematology analyzer that performs blood cell differentials. It offers a suitable solution for laboratories with small workloads (Photo courtesy of Sysmex)

Microscopic examination of peripheral blood smear (PBS) is essential in clinical hematology laboratories. Manual counting is, however, inefficient because the process is technically demanding and labor-intensive resulting in long turnaround time (TAT), and the results may be subjective with inter-observer variation.

Digital morphology (DM) analyzers can provide analysis of cell morphology (pre-classification) with reduced TAT and inter-observer variation. In a recent study, DM analyzers showed advantages over manual counting in laboratory efficiency including shortened TAT. DM analyzers can be used mainly in large-volume laboratories, and they are too large and expensive to be used in small to medium-volume laboratories.

Medical Laboratory Scientists at the Konkuk University School of Medicine (Seoul, Korea) obtained PBS slides from healthy individuals, spanning normal white blood cell (WBC) range including mild leukopenia (2.0–4.0 × 109/L) and mild leukocytosis (10.0–15.0 × 109/L). WBC counts in these samples were 3.90 × 109/L, 5.19 × 109/L, 6.72 × 109/L, 8.72 × 109/L, and 10.78 × 109/L, respectively. Venous whole blood samples were collected and were used for complete blood counts in XN-9000 (Sysmex, Kobe, Japan), and PBS slides were made and reviewed for WBC differentials.

The Sysmex CellaVision DC-1 (DC1) is a newly launched digital morphology analyzer that was developed mainly for small to medium-volume laboratories. The scientists evaluated the precision, qualitative performance, comparison of cell counts between DC-1 and manual counting, and turnaround time (TAT) of DC-1. Pre-classification on DC-1 included total 18 cell classes (12 WBC classes and six non-WBC classes). The 12 WBC classes include blasts, promyelocytes, myelocytes, metamyelocytes, band neutrophils, segmented neutrophils, lymphocytes, monocytes, eosinophils, basophils, variant lymphocytes, and plasma cells. The six non-WBC classes include nucleated RBCs (nRBCs), smudge cells, artifact, giant platelet, platelet aggregation, and unidentified cells.

The investigators reported that DC-1 showed excellent precision (%CV, 0.0%–3.5%), high specificity (98.9%–100.0%), and high negative predictive value (98.4%–100.0%) in 18 cell classes (12 WBC classes and six non-WBC classes). However, DC-1 showed 0% of positive predictive value in seven cell classes (metamyelocytes, myelocytes, promyelocytes, blasts, plasma cells, nucleated red blood cells, and unidentified). The largest absolute mean differences (%) of DC-1 versus manual counting was 2.74. Total TAT (min:s) was comparable between DC-1 (8:55) and manual counting (8:55).

The authors concluded that their study showed that DC-1 has a reliable analytical performance in all cell classes, and it can be used in small-to medium-volume laboratories for providing assist of manpower in daily practice of PBS review. However, DC-1 may make unnecessary workload for cell verification in some cell classes. The study was published on October 31, 2022 in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
Konkuk University School of Medicine
Sysmex

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.